Article

FDA committee gives AMD drug favorable review; delays formal vote for now

The FDA's Dermatologic & Ophthalmic Drugs Advisory Committee met Aug. 27 to begin a priority review of the clinical submission for the investigational drug pegaptanib sodium injection (Macugen) for the treatment of neovascular age-related macular degeneration (AMD).

The FDA's Dermatologic & Ophthalmic Drugs Advisory Committee met Aug. 27 to begin a priority review of the clinical submission for the investigational drug pegaptanib sodium injection (Macugen) for the treatment of neovascular age-related macular degeneration (AMD).

In accordance with the rolling submission process of a priority review, the advisory committee did not take a formal vote immediately. Co-developed by Eyetech Pharmaceuticals Inc. and Pfizer Ophthalmics, pegaptanib sodium received priority review status from the FDA since it is a product that addresses an unmet medical need.

Eyetech and Pfizer submitted the new drug application (NDA) for pegaptanib sodium on June 17. The FDA takes into consideration the deliberations of the advisory committee as part of its review of NDAs.

Eyetech's lead clinical trials include two phase II/III pivotal clinical trials for the use of pegaptanib sodium in the treatment of neovascular AMD; a phase II clinical trial for the use of pegaptanib sodium for the treatment of diabetic macular edema; and a phase II clinical trial for the use of pegaptanib sodium in the treatment of retinal vein occlusion.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
© 2025 MJH Life Sciences

All rights reserved.